CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.

Montserrat PuigdellosesMarc Garcia-MoureSara LabianoVirginia LaspideaMarisol Gonzalez-HuarrizMarta ZalacainLucia MarrodanNaiara Martinez-VelezDaniel De la NavaIker AusejoSandra Hervás-StubbsGuillermo HerradorZhiHong ChenDolores HambardzumyanAna Patino GarciaHong JiangCandelaria Gomez-ManzanoJuan FueyoJaime Gállego Pérez-LarrayaMarta Marija Alonso

Published in: Journal for immunotherapy of cancer (2022)

In summary, our data demonstrated the efficacy of Delta-24-ACT combined with a PD-L1 inhibitor in murine glioma models. Moreover, the data underscore the potential to combine local immunovirotherapy with ICIs as an effective therapy for poorly infiltrated tumors.

Keyphrases

immune response
electronic health record
big data
cancer therapy
data analysis
toll like receptor
risk assessment
deep learning